This week, Bioventus announced plans to sell its wound business; Pfizer and Thermo Fisher Scientific partnered to increase cancer screening access; and the FDA expanded the magnetic resonance imaging labeling for Abbott’s Eterna spinal cord stimulator.

Global sales of orthobiologics products are expected to reach $2.8bn by 2024, a CAGR of 3.2%, led by the rising aging population and musculoskeletal disease.

The global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration is expected to reach $2.3bn by 2023, according to a new report by Informa's Meddevicetracker. This highly competitive market, which is led by Arthrex and other large and smaller players, continues to grow amid the rising prevalence of musculoskeletal soft tissue injuries and osteoarthritis. High prices of implants, the limited availability of donated tissue and limited reimbursement for synthetic scaffolds are limiting growth in this market.

Girls with elevated urinary concentrations of methyl paraben and propyl paraben biomarkers at age nine showed signs of entering puberty earlier than their peers, according to a UC Berkeley study focused on possible adverse impacts of personal-care product use. More news in brief.